Latest Commercialization News

Tryptamine Therapeutics has secured ethics approval to begin a pioneering clinical trial of TRP-8803, an IV-infused psilocin treatment, targeting adult patients with Binge Eating Disorder. The trial aims to evaluate safety and efficacy, with initial results expected by the end of 2025.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

Amaero has completed commissioning its second advanced atomizer at its Tennessee facility, reinforcing its production capacity and reaffirming strong revenue visibility for FY2026. The company’s strategic investments position it as a key domestic supplier in the US advanced manufacturing sector.

GreenHy2 Limited has successfully raised nearly $1 million through a strategic share placement aimed at fast-tracking its innovative energy storage products, including hybridised graphene batteries and hydrogen solutions.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Eden Innovations is expanding the use of its EdenCrete® concrete additives across major infrastructure projects in Colorado, including a high-rise, public pools, and a massive highway upgrade.

Waterco Limited has disclosed a historical breach of ASX Listing Rule 10.1 involving lease agreements with a related party, prompting plans to seek retrospective shareholder approval at its 2025 AGM.

Eden Innovations is set to consolidate its shares and launch a $6.6 million entitlement offer to reduce debt and fund global expansion of its EdenCrete® and OptiBlend® products.

GPT Group has announced an estimated distribution of 12.0 cents per stapled security for the first half of 2025, setting the stage ahead of its interim results release in August.

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

AIC Mines has awarded a fixed-price $77.6 million contract to GR Engineering to expand its Eloise processing plant capacity from 725,000 to 1.1 million tonnes per annum, with construction set to begin in October 2025 and commissioning expected by late 2026.

Pure Hydrogen Corporation has officially handed over the Taurus Hydrogen Fuel Cell Prime Mover to Barwon Water, marking a milestone in Australia’s hydrogen transport adoption and supporting Barwon Water’s net zero emissions goal by 2030.